zirconium Zr 89-DFO-emapalumab

{
  "id": "MLC-T-ONC-017687",
  "term": "zirconium Zr 89-DFO-emapalumab",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate comprised of emapalumab, a human monoclonal antibody directed against the cytokine interferon-gamma (IFN-gamma; IFNg), linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of Zr89-DFO-emapalumab, the emapalumab moiety specifically targets and binds to IFNg. Upon binding, the radioisotope moiety is detected using PET, thereby allowing the imaging of IFNg. This may help detect lesions and assess response to immunotherapeutic agents. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system.",
  "synonyms": [
    "[89Zr]-DFO-emapalumab",
    "zirconium Zr 89 DFO-emapalumab",
    "Zr89-DFO-emapalumab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/zirconium-zr-89-dfo-emapalumab/"
}